-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLB-3000 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLB-3000 in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLB-3000 in Hepatitis B Drug Details: CLB-3000 is under development for the...
-
Product Insights
NewNet Present Value Model: Lisata Therapeutics Inc’s Xowna
Empower your strategies with our Net Present Value Model: Lisata Therapeutics Inc's Xowna report and make more profitable business decisions.Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Lisata Therapeutics Inc's Xowna...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LSTA-201
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LSTA-201 Drug Details CLBS-201 is under development for the treatment of chronic kidney disease,...
-
Product Insights
Net Present Value Model: Honedra
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Honedra Drug Details Honedra (CLBS-12) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LSTA-16
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LSTA-16 Drug Details Xowna (CLBS-16) is under development for the treatment of coronary microvascular...